Adhera Therapeutics, Inc. (OTCPK:ATRX) enter into letter of intent to acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin from Bio Innovation Group on July 19, 2022. While best efforts are anticipated to advance the Heads of Terms agreement to an executed definitive agreement pursuant to which Adhera will acquire PGT, no assurances of such a development are expressed, implied, or guaranteed.